Darzalex Biosimilar
Darzalex Biosimilar
Darzalex (daratumumab) is a monoclonal antibody targeting CD38 and is an established therapeutic option for the treatment of multiple myeloma, offering significant clinical benefits as a monotherapy and in combination with other treatments.
Biocognate has developed several single-cell clones expressing high levels of daratumumab for biosimilar product development. These clones have documented evidence of monoclonality and demonstrate protein titers in the range of 5 – 6 g/L in a shake-flask fed-batch process, without any prior cell culture process development.
The protein titers obtained on Day 14 of the fed-batch study conducted in shake flasks, without cell culture process optimization, are presented in the table below for the top three single-cell clones.
An assessment of the charge variant distribution and glycan profiles of daratumumab produced by these clones indicates that minimal or no process development may be required to achieve biosimilarity, subject to comprehensive analytical and functional comparability assessments. This offers the potential to preserve the high productivity of the selected clones while minimizing process-related changes, thereby supporting improved product yields during manufacturing.
Biocognate offers these high-producing daratumumab clones for R&D and commercial in-licensing. In addition, Biocognate can provide customized upstream and downstream process development services for any of these clones, tailored to the specific requirements of the client.
Interested companies are invited to contact the Biocognate team to discuss clone availability, supporting characterization data, and potential collaboration opportunities.
